209 related articles for article (PubMed ID: 23436844)
21. Hepatobiliary phase in cirrhotic patients with different Model for End-stage Liver Disease score: comparison of the performance of gadoxetic acid to gadobenate dimeglumine.
Khouri Chalouhi C; Vernuccio F; Rini F; Duca P; Tuscano B; Brancatelli G; Vanzulli A
Eur Radiol; 2019 Jun; 29(6):3090-3099. PubMed ID: 30547205
[TBL] [Abstract][Full Text] [Related]
22. Preoperative MRI of potential living-donor-related liver transplantation using a single dose of gadobenate dimeglumine.
Lim JS; Kim MJ; Kim JH; Kim SI; Choi JS; Park MS; Oh YT; Yoo HS; Lee JT; Kim KW
AJR Am J Roentgenol; 2005 Aug; 185(2):424-31. PubMed ID: 16037515
[TBL] [Abstract][Full Text] [Related]
23. Incorporating the hepatobiliary phase of gadobenate dimeglumine-enhanced MRI in the diagnosis of hepatocellular carcinoma: increasing the sensitivity without compromising specificity.
Cortis K; Liotta R; Miraglia R; Caruso S; Tuzzolino F; Luca A
Acta Radiol; 2016 Aug; 57(8):923-31. PubMed ID: 26567965
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of the accuracy of gadobenate dimeglumine-enhanced MR imaging in the detection and characterization of focal liver lesions.
Pirovano G; Vanzulli A; Marti-Bonmati L; Grazioli L; Manfredi R; Greco A; Holzknecht N; Daldrup-Link HE; Rummeny E; Hamm B; Arneson V; Imperatori L; Kirchin MA; Spinazzi A
AJR Am J Roentgenol; 2000 Oct; 175(4):1111-20. PubMed ID: 11000175
[TBL] [Abstract][Full Text] [Related]
25. Importance of small (< or = 20-mm) enhancing lesions seen only during the hepatic arterial phase at MR imaging of the cirrhotic liver: evaluation and comparison with whole explanted liver.
Holland AE; Hecht EM; Hahn WY; Kim DC; Babb JS; Lee VS; West AB; Krinsky GA
Radiology; 2005 Dec; 237(3):938-44. PubMed ID: 16306035
[TBL] [Abstract][Full Text] [Related]
26. Gadobenate dimeglumine-enhanced liver magnetic resonance imaging: value of hepatobiliary phase for the detection of focal liver lesions.
Fu GL; Du Y; Zee CS; Yang HF; Li Y; Duan RG; Zeng NL; Xiao DM
J Comput Assist Tomogr; 2012; 36(1):14-9. PubMed ID: 22261765
[TBL] [Abstract][Full Text] [Related]
27. Hepatic hemangiomas: difference in enhancement pattern on 3T MR imaging with gadobenate dimeglumine versus gadoxetate disodium.
Gupta RT; Marin D; Boll DT; Husarik DB; Davis DE; Feuerlein S; Merkle EM
Eur J Radiol; 2012 Oct; 81(10):2457-62. PubMed ID: 22138122
[TBL] [Abstract][Full Text] [Related]
28. Detection of hepatic hypovascular metastases: 3D gradient echo MRI using a hepatobiliary contrast agent.
Choi JY; Choi JS; Kim MJ; Lim JS; Park MS; Kim JH; Chung YE
J Magn Reson Imaging; 2010 Mar; 31(3):571-8. PubMed ID: 20187199
[TBL] [Abstract][Full Text] [Related]
29. Hepatocellular carcinoma in the cirrhotic liver: gadolinium-enhanced 3D T1-weighted MR imaging as a stand-alone sequence for diagnosis.
Hecht EM; Holland AE; Israel GM; Hahn WY; Kim DC; West AB; Babb JS; Taouli B; Lee VS; Krinsky GA
Radiology; 2006 May; 239(2):438-47. PubMed ID: 16641353
[TBL] [Abstract][Full Text] [Related]
30. Gadobenate dimeglumine-enhanced MRI of the breast: analysis of dose response and comparison with gadopentetate dimeglumine.
Knopp MV; Bourne MW; Sardanelli F; Wasser MN; Bonomo L; Boetes C; Müller-Schimpfle M; Hall-Craggs MA; Hamm B; Orlacchio A; Bartolozzi C; Kessler M; Fischer U; Schneider G; Oudkerk M; Teh WL; Gehl HB; Salerio I; Pirovano G; La Noce A; Kirchin MA; Spinazzi A
AJR Am J Roentgenol; 2003 Sep; 181(3):663-76. PubMed ID: 12933457
[TBL] [Abstract][Full Text] [Related]
31. Focal liver lesions: whether a standard dose (0.05 mmol/kg) gadobenate dimeglumine can provide the same diagnostic data as the 0.1 mmol/kg dose.
Nural MS; Gokce E; Danaci M; Bayrak IK; Diren HB
Eur J Radiol; 2008 Apr; 66(1):65-74. PubMed ID: 17555901
[TBL] [Abstract][Full Text] [Related]
32. Hepatocellular carcinoma: evaluation with dynamic and static gadobenate dimeglumine-enhanced MR imaging and histopathologic correlation.
Vogl TJ; Stupavsky A; Pegios W; Hammerstingl R; Mack M; Diebold T; Lodemann KP; Neuhaus P; Felix R
Radiology; 1997 Dec; 205(3):721-8. PubMed ID: 9393527
[TBL] [Abstract][Full Text] [Related]
33. Contrast-enhanced MR mammography: improved lesion detection and differentiation with gadobenate dimeglumine.
Pediconi F; Catalano C; Padula S; Roselli A; Dominelli V; Cagioli S; Kirchin MA; Pirovano G; Passariello R
AJR Am J Roentgenol; 2008 Nov; 191(5):1339-46. PubMed ID: 18941066
[TBL] [Abstract][Full Text] [Related]
34. Biochemical markers and MR imaging findings as predictors of crohn disease activity in patients scanned by contrast-enhanced MR enterography.
Quaia E; Cabibbo B; Sozzi M; Gennari AG; Pontello M; Degrassi F; Cova MA
Acad Radiol; 2014 Oct; 21(10):1225-32. PubMed ID: 24998692
[TBL] [Abstract][Full Text] [Related]
35. Biologic factors affecting HCC conspicuity in hepatobiliary phase imaging with liver-specific contrast agents.
Kim JY; Lee SS; Byun JH; Kim SY; Park SH; Shin YM; Lee MG
AJR Am J Roentgenol; 2013 Aug; 201(2):322-31. PubMed ID: 23883212
[TBL] [Abstract][Full Text] [Related]
36. Focal nodular hyperplasia: intraindividual comparison of dynamic gadobenate dimeglumine- and ferucarbotran-enhanced magnetic resonance imaging.
Marin D; Iannaccone R; Laghi A; Catalano C; Murakami T; Hori M; Kim T; Passariello R
J Magn Reson Imaging; 2007 Apr; 25(4):775-82. PubMed ID: 17348002
[TBL] [Abstract][Full Text] [Related]
37. MRI features of inflammatory hepatocellular adenomas on hepatocyte phase imaging with liver-specific contrast agents.
Thomeer MG; Willemssen FE; Biermann KK; El Addouli H; de Man RA; Ijzermans JN; Dwarkasing RS
J Magn Reson Imaging; 2014 May; 39(5):1259-64. PubMed ID: 23897798
[TBL] [Abstract][Full Text] [Related]
38. Effect of increasing the flip angle during the hepatocyte phase of gadobenate dimeglumine-enhanced 1.5T MRI in cirrhotic patients with hepatocellular carcinoma.
Lee EJ; Kim DJ; Cho ES; Kim KA
J Magn Reson Imaging; 2016 Mar; 43(3):713-9. PubMed ID: 26290384
[TBL] [Abstract][Full Text] [Related]
39. Comparison of Visualization Rates of LI-RADS Version 2014 Major Features With IV Gadobenate Dimeglumine or Gadoxetate Disodium in Patients at Risk for Hepatocellular Carcinoma.
Allen BC; Ho LM; Jaffe TA; Miller CM; Mazurowski MA; Bashir MR
AJR Am J Roentgenol; 2018 Jun; 210(6):1266-1272. PubMed ID: 29629800
[TBL] [Abstract][Full Text] [Related]
40. Gadoxetic acid-enhanced magnetic resonance imaging for differentiating small hepatocellular carcinomas (< or =2 cm in diameter) from arterial enhancing pseudolesions: special emphasis on hepatobiliary phase imaging.
Sun HY; Lee JM; Shin CI; Lee DH; Moon SK; Kim KW; Han JK; Choi BI
Invest Radiol; 2010 Feb; 45(2):96-103. PubMed ID: 20057319
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
